Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Design and development of a novel, thermostable, and inhalable dry powder COVID-19 vaccine

Award Number: SC2GM144157
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/20/2022
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

Design and development of a novel, thermostable, and inhalable dry powder COVID-19 vaccine - Summary Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) is a highly infectious virus known to cause the 2019 coronavirus disease (COVID-19). The disease has been declared as a global pandemic by the World Health Organization. In the United States, as of January 20, 2021, we have more than 24 million infected individuals with approximately 400,000 deaths. COVID-19 appears to be more deadly in patients with co-morbidities such as hypertension and diabetes and presents many clinical manifestations such as pneumonia, diarrhea, multiple organ failure, etc. among those infected. Moreover, the number of infections and fatality rate is expected to increase significantly over the next few months, according to the IHME model. There is an urgent global need to develop a thermostable and self-administrable vaccine. The spike protein on the surface of coronavirus is an excellent candidate for developing vaccines, has been used in the currently EUA obtained vaccines, as it plays an important role in the entry of the virus into the host cell. Liposomes are excellent drug delivery systems that can present the antigen as particulate in nature and allow the incorporation of an adjuvant that aids in the generation of a robust immune response. Further, the liposomes can be designed to be of similar size to that of the virus and the spike protein can be conjugated to the liposomal surface to mimic the natural presentation on the virus. The immune cells will internalize and process the antigen like the virus and generate neutralizing antibody titers. Most of the vaccines currently in the market require cold chain (refrigeration) to store and distribute the vaccine to maintain the efficacy and require a visit to the clinic for immunization by trained medical personnel. These serve as bottlenecks in achieving mass vaccination in a pandemic adding further stress to the hospitals and the supply chain. In addition, a major limitation is the limited ability of existing manufacturing facilities to manufacture billions of doses. In this proposal, we aim to develop a thermostable and inhalable dry powder vaccine that is easy to scale-up, eliminates the need for cold-chain storage and transport, and is self-administrable by individuals’ at-home by simple inhalation. To achieve this goal, we will pursue two aims: 1) Formulation of an inhalable and thermostable dry powder COVID-19 vaccine containing S protein-adsorbed liposomal carriers and 2) Evaluation of neutralizing mucosal and systemic IgA and IgG antibody titers after aerosol administration of dry powder COVID-19 vaccine in mice. Successful completion of this project will have a profound impact on the development of dry powder COVID-19 vaccine, particularly in exploring thermostable and inhalable vaccines that are easy to manufacture, store, and distribute, characteristics that are critical in pandemic.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	ST JOHN'S UNIVERSITY, NEW YORK	8000 UTOPIA PKWY	JAMAICA	NY	11439	QUEENS	USA	Biomedical Research and Research Training	000	3	2/25/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $164,000 )
2024	2024	ST JOHN'S UNIVERSITY, NEW YORK	8000 UTOPIA PKWY	JAMAICA	NY	11439	QUEENS	USA	Biomedical Research and Research Training	000	3	2/28/2024	NON-COMPETING CONTINUATION	$147,600
2024	2024	ST JOHN'S UNIVERSITY, NEW YORK	8000 UTOPIA PKWY	JAMAICA	NY	11439	QUEENS	USA	Biomedical Research and Research Training	001	3	6/18/2024	NON-COMPETING CONTINUATION	$16,400
														Subtotal = $164,000

Issue Date FY: 2023 ( Subtotal = $164,000 )
2023	2023	ST JOHN'S UNIVERSITY, NEW YORK	8000 UTOPIA PWY	JAMAICA	NY	11439	QUEENS	USA	Biomedical Research and Research Training	000	2	2/24/2023	NON-COMPETING CONTINUATION	$164,000
														Subtotal = $164,000

Issue Date FY: 2022 ( Subtotal = $164,000 )
2022	2022	ST JOHN'S UNIVERSITY, NEW YORK	8000 UTOPIA PWY	JAMAICA	NY	11439	QUEENS	USA	Biomedical Research and Research Training	000	1	4/20/2022	NEW	$164,000
														Subtotal = $164,000

Grand Total All Awards = $492,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Design and development of a novel, thermostable, and inhalable dry powder COVID-19 vaccine

Award Number: SC2GM144157

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/20/2022

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer